Thursday 16 October, 2025
Introduction: Type 2 diabetes is considered to be one of the most significant health problems affecting the world, and prolonged…
Read morePoster: Drug/Disease Modelling - Endocrine
Assessing Glucagon Kinetics through Nonlinear Mixed Effects Modeling
Thursday 16 October, 2025
Objectives:A concomitance of both defective insulin secretion and impaired glucagon suppression leads to the development of impaired glucose tolerance in…
Read moreAssessing insulin sensitivity, glucose effectiveness, and β-cell responsivity using an integrated glucose, insulin, and C-peptide minimal model
Thursday 16 October, 2025
Objectives: Intravenous glucose tolerance tests (IVGTT) have been widely used to investigate the glucose-insulin interaction in subjects with and without…
Read moreDevelopment of a pharmacokinetic model to predict disposition of Dutasteride in zebrafish embryos
Thursday 16 October, 2025
Objectives: In the last two decades, the zebrafish and especially its embryos gained a lot of interest as animal models…
Read moreQuantifying the rate of blood glucose changes over the acute stage of ischemic stroke among patients with diabetes.
Thursday 16 October, 2025
Objectives: Hyperglycemia (HG) during acute ischemic stroke (AIS) is associated with poor outcomes. Diabetes mellitus (DM) is an independent predictor…
Read moreEnhanced pharmacometrics model utilizes heart rate to monitor thyroid function in pediatric Graves’ disease under pharmacotherapy
Thursday 16 October, 2025
Objectives: Graves’ disease (GD) with onset in childhood or adolescence is a serious pediatric rare disease (ORPHA:525731). Leading clinical signs…
Read morePharmacometric Time-to-Event (TTE) Modeling of Diabetic Nephropathy in Type 2 Diabetes Mellitus Patients
Thursday 16 October, 2025
Objectives:Time-to-event (TTE) pharmacometric analysis has an important role in the parametric quantification of the occurrence of diabetic nephropathy. Incorporating censoring…
Read morePharmacometrics Time-to-Event (TTE) Modeling of Diabetic Nephropathy in Type 2 Diabetes Mellitus Patients
Thursday 16 October, 2025
Objectives: Time-to-event (TTE) pharmacometrics analysis has an important role in the parametric quantification of the occurrence of diabetic nephropathy. Incorporating…
Read moreModel-Based Translational Rapamycin Dose Selection to Promote Engraftment and Expansion of the Engineered Regulatory T cell (EngTreg) product GNTI-122 in Human
Thursday 16 October, 2025
Objectives: Functional and/or absolute interleukin-2 (IL-2) scarcity is implicated in many autoimmune diseases and significantly impairs regulatory T cells (Tregs)…
Read moreExposure-Response Modeling for Ipragliflozin, a Selective Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor, in Type 1 and Type 2 Diabetes Mellitus Patients
Thursday 16 October, 2025
Introduction: Ipragliflozin is a sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor which inhibits the reabsorption of glucose from kidneys and increases…
Read more